Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.

Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH.

Histopathology. 2013 Aug;63(2):225-33. doi: 10.1111/his.12156. Epub 2013 Jun 6.

PMID:
23738752
2.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

3.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
4.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
5.
6.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
7.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
8.

The prognostic importance of triple negative breast carcinoma.

Mersin H, Yildirim E, Berberoglu U, Gülben K.

Breast. 2008 Aug;17(4):341-6. doi: 10.1016/j.breast.2007.11.031. Epub 2008 May 1.

PMID:
18450442
9.

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.

PMID:
21455625
10.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

11.

Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer.

Iida T, Iwahashi M, Katsuda M, Ishida K, Nakamori M, Nakamura M, Naka T, Ojima T, Ueda K, Hayata K, Nakamura Y, Yamaue H.

Oncol Rep. 2011 May;25(5):1271-7. doi: 10.3892/or.2011.1201. Epub 2011 Mar 1.

PMID:
21369705
12.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
14.

Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.

Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA.

Breast Cancer Res Treat. 2011 Feb;126(1):1-14. doi: 10.1007/s10549-010-0867-2. Epub 2010 Apr 6.

PMID:
20369286
15.

Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.

Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, Miao X, Tang Z.

PLoS One. 2014 Apr 17;9(4):e95475. doi: 10.1371/journal.pone.0095475. eCollection 2014.

16.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

PMID:
24065473
17.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
18.

Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA.

Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21.

19.
20.

Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.

Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C.

BMC Cancer. 2012 Apr 3;12:134. doi: 10.1186/1471-2407-12-134.

Supplemental Content

Support Center